See more : Hanwha Investment & Securities Co., Ltd. (003530.KS) Income Statement Analysis – Financial Results
Complete financial analysis of TenX Keane Acquisition Corp. (TENKU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TenX Keane Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
- Vertex Pharmaceuticals Incorporated (0QZU.L) Income Statement Analysis – Financial Results
- Gulf International Services Q.P.S.C. (GISS.QA) Income Statement Analysis – Financial Results
- Zad Holding Company Q.P.S.C. (ZHCD.QA) Income Statement Analysis – Financial Results
- Ratnaveer Precision Engineering Limited (RATNAVEER.BO) Income Statement Analysis – Financial Results
- Journeo plc (JNEO.L) Income Statement Analysis – Financial Results
TenX Keane Acquisition Corp. (TENKU)
About TenX Keane Acquisition Corp.
TenX Keane Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on target businesses operating in Asia, excluding companies located or operating in mainland China, Hong Kong, or Macau. The company was founded in 2021 and is based in New York, New York.
Metric | 2023 | 2022 | 2021 |
---|---|---|---|
Revenue | 0.00 | 518.93K | 0.00 |
Cost of Revenue | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 518.93K | 0.00 |
Gross Profit Ratio | 0.00% | 100.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 138.12K | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 |
SG&A | 1.01M | 138.12K | 0.00 |
Other Expenses | 1.78M | 0.00 | 0.00 |
Operating Expenses | 1.01M | 138.12K | 0.00 |
Cost & Expenses | 1.01M | 138.12K | 0.00 |
Interest Income | 0.00 | 493.02K | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 167.90K | -25.91K | 236.56K |
EBITDA | -1.01M | -164.02K | 236.56K |
EBITDA Ratio | 0.00% | -31.61% | 0.00% |
Operating Income | -1.01M | -138.12K | 0.00 |
Operating Income Ratio | 0.00% | -26.62% | 0.00% |
Total Other Income/Expenses | 3.43M | 518.93K | -10.11K |
Income Before Tax | 2.42M | 380.81K | -10.11K |
Income Before Tax Ratio | 0.00% | 73.38% | 0.00% |
Income Tax Expense | -167.89K | -518.93K | 0.00 |
Net Income | 2.42M | 899.74K | -10.11K |
Net Income Ratio | 0.00% | 173.38% | 0.00% |
EPS | 0.27 | 0.10 | 0.00 |
EPS Diluted | 0.27 | 0.10 | 0.00 |
Weighted Avg Shares Out | 8.95M | 9.02M | 8.14M |
Weighted Avg Shares Out (Dil) | 8.95M | 9.02M | 8.14M |
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination
TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination
Source: https://incomestatements.info
Category: Stock Reports